



Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 4, 2026

NEW YORK--(BUSINESS WIRE)--Feb. 4, 2026-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 2,820 shares of the Company's common stock to one new employee (the "Inducement Grant") on February 2, 2026 (the "Grant Date"). The Inducement Grant has been granted pursuant to the Company's 2025 Inducement Plan. The Inducement Grant was granted as an inducement material to this individual entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Grant has an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grant will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and 1/48 of the total award each month thereafter over the following three years, subject to the employee's continued employment with Neurogene through the applicable vesting dates.

About Neurogene

The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit www.neurogene.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20260204466670/en/): <https://www.businesswire.com/news/home/20260204466670/en/>

Company Contact:

Mike Devine
Executive Director, Corporate Communications
michael.devine@neurogene.com

Investor Contact:

Argot Partners
Neurogene@argotpartners.com

Source: Neurogene Inc.